Merck’s Keytruda may be the most talked about drug facing loss of exclusivity but it’s far from the only one, as several of ...

Lydia E. Pinkham’s Vegetable Compound was one of thousands of popular and lucrative patent medicines—health concoctions dreamed up by chemists, housewives, and entrepreneurs—that took the ...

As biosimilar versions of a big-selling Johnson & Johnson medicine reach the U.S. market, the health care giant accused one ...

In recent months China’s progress in artificial intelligence has stunned the world. A quieter yet equally significant shift ...

SHANGHAI, Feb 9 (Reuters) - China's healthcare regulator on Sunday defended the efficacy of off-patent medicines it had approved to be distributed through the country's public hospitals ...

GLEN ALLEN, Va. - Adial Pharmaceuticals, Inc. (NASDAQ:ADIL), a biopharmaceutical company specializing in addiction treatment with a current market capitalization of $5 million, has been granted a new ...

Adial Pharmaceuticals, Inc. (NASDAQ:ADIL) announced patent number 12,221,654 was issued on February 11, 2025, by the United ...

Milestone’s NDA for CARDAMYST is currently under review at the FDA with a Prescription Drug User Fee Act (PDUFA) target date of March 27, 2025. The Company continues to advance commercial preparations ...

The breakthrough in drug delivery hinges on the development of nanoarchaeosomes, which are nanoparticles loaded with ...